[ad_1] Efficacy signals observed will not achieve ESSA’s target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens  A futility analysis conducted as part of a protocol-specified interim review of the […]

[ad_1] SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC, Sept. 11, 2024 /PRNewswire/ – ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for treatment of prostate […]